单位:[1]E Tennessee State Univ, James H Quillen Coll Med, Div Infect Dis, Dept Internal Med, Johnson City, TN 37614 USA[2]Capital Med Univ, Dept Crit Care Unit, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[3]Soochow Univ, Sch Med, Dept Biochem & Mol Biol, Suzhou, Peoples R China[4]GalPharma, Takamatsu, Kagawa, Japan[5]Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Takamatsu, Kagawa 760, Japan[6]James H Quillen VA Med Ctr, Dept Vet Affairs, Hepatitis HCV HIV Program, Johnson City, TN USA
HCV is remarkable at disrupting human immunity to establish chronic infection. The accumulation of Treg cells at the site of infection and upregulation of inhibitory signaling pathways (such as T-cell Ig and mucin domain protein-3 (Tim-3) and galectin-9 (Gal-9)) play pivotal roles in suppressing antiviral effector T (Teff) cells that are essential for viral clearance. While Tim-3/Gal-9 interactions have been shown to negatively regulate Teff cells, their role in regulating Treg cells is poorly understood. To explore how Tim-3/Gal-9 interactions regulate HCV-mediated Treg-cell development, here we provide pilot data showing that HCV-infected human hepatocytes express higher levels of Gal-9 and TGF-, and upregulate Tim-3 expression and regulatory cytokines TGF-/IL-10 in co-cultured human CD4+ T cells, driving conventional CD4+ T cells into CD25+Foxp3+ Treg cells. Additionally, recombinant Gal-9 protein can transform TCR-activated CD4+ T cells into Foxp3+ Treg cells in a dose-dependent manner. Importantly, blocking Tim-3/Gal-9 ligations abrogates HCV-mediated Treg-cell induction by HCV-infected hepatocytes, suggesting that Tim-3/Gal-9 interactions may regulate human Foxp3+ Treg-cell development and function during HCV infection.
基金:
NIH NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [1R15A1084057]; NIH NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK093526]; ETSU Major Research Grant; ETSU-Wake Forest University Pilot Collaborative Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R15AI084057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK093526] Funding Source: NIH RePORTER
第一作者单位:[1]E Tennessee State Univ, James H Quillen Coll Med, Div Infect Dis, Dept Internal Med, Johnson City, TN 37614 USA[2]Capital Med Univ, Dept Crit Care Unit, Beijing Friendship Hosp, Beijing, Peoples R China
通讯作者:
通讯机构:[1]E Tennessee State Univ, James H Quillen Coll Med, Div Infect Dis, Dept Internal Med, Johnson City, TN 37614 USA[6]James H Quillen VA Med Ctr, Dept Vet Affairs, Hepatitis HCV HIV Program, Johnson City, TN USA[*1]E Tennessee State Univ, James H Quillen Coll Med, Div Infect Dis, Dept Internal Med, POB 70622, Johnson City, TN 37614 USA
推荐引用方式(GB/T 7714):
Ji Xiao J.,Ma Cheng J.,Wang Jia M.,et al.HCV-infected hepatocytes drive CD4+CD25+Foxp3+regulatory T-cell development through the Tim-3/Gal-9 pathway[J].EUROPEAN JOURNAL of IMMUNOLOGY.2013,43(2):458-467.doi:10.1002/eji.201242768.
APA:
Ji, Xiao J.,Ma, Cheng J.,Wang, Jia M.,Wu, Xiao Y.,Niki, Toshiro...&Yao, Zhi Q..(2013).HCV-infected hepatocytes drive CD4+CD25+Foxp3+regulatory T-cell development through the Tim-3/Gal-9 pathway.EUROPEAN JOURNAL of IMMUNOLOGY,43,(2)
MLA:
Ji, Xiao J.,et al."HCV-infected hepatocytes drive CD4+CD25+Foxp3+regulatory T-cell development through the Tim-3/Gal-9 pathway".EUROPEAN JOURNAL of IMMUNOLOGY 43..2(2013):458-467